Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4644817 | 0.88 | ALDH1A1 (0.56) | THRBSMN1; SMN2TDP1MEN1KMT2A | |
| SCHEMBL3817262 | 0.82 | ALDH1A1 (0.51) | THRBSMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL27590392 | 0.80 | CA1 (0.56) | THRBSMN1; SMN2TDP1MEN1KMT2A | |
| SCHEMBL14499650 | 0.78 | CA1 (0.54) | THRBSMN1; SMN2TDP1MEN1KMT2A | |
| SCHEMBL31120657 | 0.76 | CA1 (0.57) | THRBSMN1; SMN2TDP1MEN1KMT2A | |
| SCHEMBL5201127 | 0.76 | CA1 (0.57) | THRBSMN1; SMN2TDP1MEN1KMT2A | |
| SCHEMBL29096884 | 0.73 | CYP19A1 (0.56) | THRBTDP1MEN1KMT2ACA1 | |
| SCHEMBL15488654 | 0.73 | KMT2A (0.57) | THRBSMN1; SMN2TDP1MEN1KMT2A | |
| SCHEMBL6109028 | 0.73 | ALDH1A1 (0.51) | THRBSMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL6109023 | 0.73 | ALDH1A1 (0.51) | THRBSMN1; SMN2MEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662999-B2 | Recognition of oligosaccharide molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases | NATIONAL INSTITUTES OF HEALTH (NIH) (US) | 2010-02-16 | — | — | US | disclosed |
| EP-1945241-A2 | TREATMENT OF PROLIFERATIVE DISORDERS WITHPOLYCATIONIC AGENTS | MediQuest Therapeutics, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070232674-A1 | RECOGNITION OF OLIGIOSACCARIDE MOLECULAR TARGETS BY POLYCATIONIC SMALL MOLECULE INHIBITORS AND TREATMENT OF IMMUNOLOGICAL DISORDERS AND INFECTIOUS DISEASES | MEDIQUEST THERAPEUTICS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| WO-2007048120-A2 | TREATMENT OF PROLIFERATIVE DISORDERS WITH POLYCATIONIC AGENTS | MEDIQUEST THERAPEUTICS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070093424-A1 | RECOGNITION OF OLIGIOSACCARIDE MOLECULAR TARGETS BY POLYCATIONIC SMALL MOLECULE INHIBITORS AND TREATMENT OF IMMUNOLOGICAL DISORDERS AND INFECTIOUS DISEASES | MEDIQUEST THERAPEUTICS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-7199267-B1 | Recognition of oligiosaccaride molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases | MEDIQUEST THERAPEUTICS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232674-A1 | RECOGNITION OF OLIGIOSACCARIDE MOLECULAR TARGETS BY POLYCATIONIC SMALL MOLECULE INHIBITORS AND TREATMENT OF IMMUNOLOGICAL DISORDERS AND INFECTIOUS DISEASES | CD14, CD74, OSTC | THRB 3544/4885SMN1; SMN2 3794/4885TDP1 3550/4885 |
| US-20070093424-A1 | RECOGNITION OF OLIGIOSACCARIDE MOLECULAR TARGETS BY POLYCATIONIC SMALL MOLECULE INHIBITORS AND TREATMENT OF IMMUNOLOGICAL DISORDERS AND INFECTIOUS DISEASES | CD14, CD74, OSTC | THRB 3544/4885SMN1; SMN2 3794/4885TDP1 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.